keyword
MENU ▼
Read by QxMD icon Read
search

Exemestane

keyword
https://www.readbyqxmd.com/read/29455298/patient-reported-predictors-of-early-treatment-discontinuation-treatment-related-symptoms-and-health-related-quality-of-life-among-postmenopausal-women-with-primary-breast-cancer-randomized-to-anastrozole-or-exemestane-on-ncic-clinical-trials-group-cctg-ma
#1
Lynne I Wagner, Fengmin Zhao, Paul E Goss, Judith-Anne W Chapman, Lois E Shepherd, Timothy J Whelan, Bassam I Mattar, Jose A Bufill, William C Schultz, Irving E LaFrancis, Gauri G Nagargoje, Radhakrishna Vemuri, Daniel A Nikcevich, George W Sledge, David Cella
PURPOSE: Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane. METHODS: MA...
February 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29442014/improvement-of-treatment-outcomes-after-implementation-of-comprehensive-pharmaceutical-care-in-breast-cancer-patients-receiving-everolimus-and-exemestane
#2
M Todo, S Ueda, S Osaki, I Sugitani, T Takahashi, M Takahashi, H Makabe, T Saeki, Y Itoh
Combination therapy with everolimus and an aromatase inhibitor such as exemestane is an effective treatment option for advanced or recurrent breast cancer. However, the therapy is often limited because of the occurrence of severe adverse events (AEs), including oral mucositis, interstitial lung disease, diarrhea, and rash. Therefore, early management of AEs is extremely important to obtain maximum treatment outcome. We investigated here the effects of comprehensive pharmaceutical care for prevention of severe AEs on patient's quality-of-life (QOL) and continuation of therapy...
February 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29441507/economic-evaluation-of-fulvestrant-500-mg-compared-to-generic-aromatase-inhibitors-in-patients-with-advanced-breast-cancer-in-sweden
#3
Ugne Sabale, Mattias Ekman, Daniel Thunström, Claire Telford, Christopher Livings
OBJECTIVES: In Sweden, breast cancer (BC) represents 30% of newly diagnosed cancers and is the most common cancer in women. For hormone-dependent BC, endocrine therapies varying in efficacy and price are available. The aim of this study is to assess the cost effectiveness of fulvestrant 500 mg as a second-line hormonal therapy for postmenopausal women with estrogen receptor-positive metastatic or locally advanced BC versus letrozole, anastrozole, and exemestane in Sweden. METHODS: A three-state (pre-progression, post-progression, and death) partitioned-survival model was used to estimate progression-free (PFS) and overall survival (OS) by extrapolating trial results beyond the trial period to capture costs and benefits over a lifetime perspective...
December 2017: PharmacoEconomics Open
https://www.readbyqxmd.com/read/29394793/-a-case-of-long-term-survival-of-breast-cancer-with-lymph-node-and-liver-metastases-treated-with-sequential-anti-her2-drugs-chemotherapy-and-endocrine-therapy
#4
Takashi Katsumori, Hisami Ohshima, Hiromitsu Hamaguchi, Shinichi Yamamoto, Yukika Tsukamoto, Tomohiro Iwanaga, Susumu Ohkawara
A 50s-year-old woman underwent left partial mastectomy with axillary lymphadenectomy for breast cancer. Histological examination indicated invasive ductal carcinoma, pT1c, pN0, Stage I , ly(+), ER(+), PgR(+). She received adjuvant therapy with tamoxifen and 50 Gy of irradiation to the residual breast. Four years after mastectomy, she was found to have left Rotter lymph node metastasis; then, anastrozole was administered instead of tamoxifen. Nine months later, she was found to have liver metastasis. Immunohistostaining revealed that the breast cancer was HER2-positive; she received AC followed by paclitaxel(PTX)with trastuzumab(T), and achieved complete response(CR)...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394600/-efficacy-and-safety-of-everolimus-plus-exemetane-in-postmenopausal-endocrine-responsive-metastatic-breast-cancer-patients
#5
Noriko Maeda, Shigeru Yamamoto, Yoko Sato, Kazuhiko Sakamoto, Nobuaki Suzuki, Shigeru Takeda, Yukiko Nagashima, Hidefumi Kubo, Hiroaki Nagano
Everolimus and exemestane combination therapy represents a treatment option for estrogen receptor(ER)-positive metastatic breast cancer. We evaluated the efficacy and safety of everolimus and exemestane therapy, retrospectively. After a median follow-up of 10.5 months, the median progression-free survivalin patients was 4.7 months. The clinicalbenefit rate was 27%and the disease controlrate was 64%. The most common all-grade adverse events(AEs)were stomatitis(82%) and non-infectious lung disease(27%). The most commonB3 grade AEs were cellulitis(18%)and hyperglycemia(18%)...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29354686/e2112-randomized-phase-iii-trial-of-endocrine-therapy-plus-entinostat-placebo-in-patients-with-hormone-receptor-positive-advanced-breast-cancer
#6
REVIEW
Sri Lakshmi Hyndavi Yeruva, Fengmin Zhao, Kathy D Miller, Amye J Tevaarwerk, Lynne I Wagner, Robert J Gray, Joseph A Sparano, Roisin M Connolly
Endocrine therapies are effective in the treatment of hormone receptor (HR)-positive breast cancer, however, de novo or acquired treatment resistance is a significant clinical problem. A potential mechanism of resistance involves changes in gene expression secondary to epigenetic modifications, which might be reversed with the use of histone deacetylase (HDAC) inhibitors such as entinostat. The ENCORE 301 phase II randomized, placebo-controlled study demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS), with the addition of entinostat to exemestane in patients with HR-positive advanced breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI)...
2018: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29344106/overall-survival-and-progression-free-survival-with-endocrine-therapy-for-hormone-receptor-positive-her2-negative-advanced-breast-cancer-review
#7
REVIEW
Tomás Reinert, Carlos H Barrios
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuvant/neoadjuvant setting. Second-line was defined as endocrine therapy for advanced breast cancer following disease progression on endocrine therapy for advanced disease...
November 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29306943/clinically-observed-estrogen-receptor-alpha-mutations-within-the-ligand-binding-domain-confer-distinguishable-phenotypes
#8
Shanhang Jia, Mark T Miedel, Marilyn Ngo, Ryan Hessenius, Ning Chen, Peilu Wang, Amir Bahreini, Zheqi Li, Zhijie Ding, Tong Ying Shun, Daniel M Zuckerman, D Lansing Taylor, Shannon L Puhalla, Adrian V Lee, Steffi Oesterreich, Andrew M Stern
OBJECTIVE: Twenty to fifty percent of estrogen receptor-positive (ER+) metastatic breast cancers express mutations within the ER ligand-binding domain. While most studies focused on the constitutive ER signaling activity commonly engendered by these mutations selected during estrogen deprivation therapy, our study was aimed at investigating distinctive phenotypes conferred by different mutations within this class. METHODS: We examined the two most prevalent mutations, D538G and Y537S, employing corroborative genome-edited and lentiviral-transduced ER+ T47D cell models...
January 6, 2018: Oncology
https://www.readbyqxmd.com/read/29287126/comparison-of-changes-in-the-lipid-profiles-of-eastern-chinese-postmenopausal-women-with-early-stage-breast-cancer-treated-with-different-aromatase-inhibitors-a-retrospective-study
#9
Wei Tian, Miaowei Wu, Yongchuan Deng
Cardiovascular morbidity is closely associated with serum lipid level. We aimed to investigate the effects of different aromatase inhibitors, including letrozole, anastrozole, and exemestane, on the lipid profile of eastern Chinese breast cancer patients. We evaluated a retrospective cohort of eastern Chinese postmenopausal women with early-stage breast cancer who received aromatase inhibitors. A total of 116 postmenopausal women with early-stage breast cancer without prior cardiovascular disease were included...
December 29, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29284708/esr1-methylation-a-liquid-biopsy-based-epigenetic-assay-for-the-follow-up-of-patients-with-metastatic-breast-cancer-receiving-endocrine-treatment
#10
Sofia Mastoraki, Areti Strati, Eleni Tzanikou, Maria Chimonidou, Helen Politaki, Alexandra Voutsina, Amanda Psyrri, Vasilis Georgoulias, Evi S Lianidou
PURPOSE: Liquid biopsy provides real-time monitoring of tumor evolution and response to therapy through analysis of CTCs and plasma-ctDNA. ESR1 epigenetic silencing potentially affects response to endocrine treatment. We evaluated ESR1 methylation in CTCs and paired plasma-ctDNA. We evaluated ESR1 methylation in CTCs and paired plasma-ctDNA as a potential biomarker for response to everolimus/exemestane treatment. EXPERIMENTAL DESIGN: A highly sensitive and specific real-time MSP assay for ESR1 methylation was developed and validated in: a) 65 primary breast tumors (FFPEs), b) EpCAM+ CTC-fractions (122 patients and 30 healthy donors; HD), c) plasma-ctDNA (108 patients and 30HD), d) in CTCs (CellSearch®) and in paired plasma-ctDNA for 58 BrCa patients...
December 28, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29274617/outcomes-in-women-with-invasive-ductal-or-invasive-lobular-early-stage-breast-cancer-treated-with-anastrozole-or-exemestane-in-cctg-ncic-ctg-ma-27
#11
K Strasser-Weippl, G Sudan, R Ramjeesingh, L E Shepherd, J O'Shaughnessy, W R Parulekar, P E R Liedke, B E Chen, P E Goss
BACKGROUND: Histological subtype, (invasive ductal breast cancer (IDBC)/invasive lobular breast cancer (ILBC)), might be a marker for differential response to endocrine therapy in breast cancer. METHODS: Clinical trial MA.27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer. We evaluated IDBC versus ILBC (based on original pathology reports) as predictor for event-free survival (EFS) and overall survival (OS)...
December 20, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29229551/modulation-of-reactive-oxygen-species-via-erk-and-stat3-dependent-signalling-are-involved-in-the-response-of-mesothelioma-cells-to-exemestane
#12
Barbara Nuvoli, Emanuela Camera, Arianna Mastrofrancesco, Stefania Briganti, Rossella Galati
Pleural mesothelioma is a deadly form of cancer. The prognosis is extremely poor due to the limited treatment modalities. Uptake of asbestos fibres, the leading cause of mesothelioma, lead to the accumulation of reactive-oxygen-species (ROS). Interestingly, increasing ROS production by using ROS-generating drugs may offer a strategy to selectively trigger cell death. Exemestane, an aromatase inhibitor, has previously shown anti-tumor properties in mesothelioma preclinical models suggesting a role of G protein-coupled receptor 30 (GPR30) in the drug response...
December 8, 2017: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/29221608/a-case-of-eruptive-disseminated-porokeratosis-in-a-cancer-patient-after-trastuzumab-and-exemestane-treatment-cancer-related-or-drug-induced-phenomenon
#13
C Mangas, V Espeli, R Blum
No abstract text is available yet for this article.
December 5, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/29177605/evaluation-of-applying-ihc4-as-a-prognostic-model-in-the-translational-study-of-intergroup-exemestane-study-ies-pathies
#14
M C U Cheang, J M Bliss, G Viale, V Speirs, C Palmieri, A Shaaban, P E Lønning, J Morden, N Porta, J Jassem, C J van De Velde, B B Rasmussen, D Verhoeven, J M S Bartlett, R C Coombes
BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to assess the role of immunohistochemical (IHC)4 score in determining the relative sensitivity to either tamoxifen or sequential treatment with tamoxifen and exemestane. PATIENTS AND METHODS: Primary tumour samples were available for 1274 patients (27% of IES population)...
November 24, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29177573/triptorelin-a-review-of-its-use-as-an-adjuvant-anticancer-therapy-in-early-breast-cancer
#15
James E Frampton
A 1-month formulation of the gonadotrophin-releasing hormone agonist (GnRHa) triptorelin (Decapeptyl®) has been approved in the EU as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor (AI), of endocrine-responsive, early-stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. This indication reflects the results of the 5-year SOFT and TEXT studies, especially SOFT, in which ovarian function suppression (OFS; mainly achieved with triptorelin) added to tamoxifen provided a significant benefit in the overall study population of premenopausal patients only after adjusting for prognostic factors...
December 2017: Drugs
https://www.readbyqxmd.com/read/29141561/steroidal-anticancer-agents-an-overview-of-estradiol-related-compounds
#16
Renata Minorics, Istvan Zupko
Research of steroidal compounds as anticancer agents started almost 50 years ago. During the past decades several innovative new steroids, like cyproterone, finasteride, estramustin, exemestane and fulvestrant have successfully become part of routine clinical practice. Meanwhile, a vast amount of new information have accumulated about the functions of the endogenous steroid system (including the characterization of enzymes, receptors, transcription pathways, etc.) and about the role of steroids in carcinogenesis...
November 13, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29137418/a-randomized-phase-ii-study-of-aromatase-inhibitors-plus-metformin-in-pre-treated-postmenopausal-patients-with-hormone-receptor-positive-metastatic-breast-cancer
#17
Yannan Zhao, Chengcheng Gong, Zhonghua Wang, Jian Zhang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Ting Li, Biyun Wang, Xichun Hu
Background: Everolimus significantly improves progression-free survival (PFS) and has been approved to use in aromatase inhibitor pretreated patients with hormone receptor positive advanced breast cancer. Metformin has been shown to inhibit mTOR pathway, with more favorable safety profile, leading to this hypothesis-generating trial to assess whether metformin enhances the efficacy of aromatase inhibitors. Methods: 60 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer were randomly assigned 1:1 to aromatase inhibitor (exemestane 25mg/d or letrozole 2...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29128813/effect-of-aromatase-inhibitors-on-learning-and-memory-and-modulation-of-hippocampal-dickkopf-1-and-sclerostin-in-female-mice
#18
Saima Zameer, Divya Vohora
BACKGROUND: There has been conflicting reports on the effect of third generation aromatase inhibitors on cognition in estrogen-deficient states. Since aromatase inhibitors themselves cause estrogen deprivation, the present work was designed to evaluate the comparative effect of three aromatase inhibitors on behavioral measures of learning and memory in female mice. Further, in view of the reports of estrogen and Wnt signaling pathway in cognition, the role of two Wnt signaling antagonists (dickkopf-1 and sclerostin) in mediation of cognitive effects of aromatase inhibitors was evaluated...
December 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29128193/vitamin-d-levels-vitamin-d-receptor-polymorphisms-and-inflammatory-cytokines-in-aromatase-inhibitor-induced-arthralgias-an-analysis-of-cctg-ma-27
#19
Polly Niravath, Bingshu Chen, Judy-Anne W Chapman, Sandeep K Agarwal, Robert L Welschhans, Tim Bongartz, Krishna R Kalari, Lois E Shepherd, John Bartlett, Kathleen Pritchard, Karen Gelmon, Susan G Hilsenbeck, Mothaffar F Rimawi, C Kent Osborne, Paul E Goss, James N Ingle
BACKGROUND: Approximately half of women taking aromatase inhibitor (AI) therapy develop AI-induced arthralgia (AIA), and many might discontinue AI therapy because of the pain. Using plasma samples from the MA.27 study, we assessed several factors potentially associated with AIA. PATIENTS AND METHODS: MA.27 is a phase III adjuvant trial comparing 2 AIs, exemestane versus anastrozole. Within an 893-participant nested case-control AIA genome-wide association study, we nested a 72 AIA case-144 control assessment of vitamin D plasma concentrations, corrected for seasonal and geographic variation...
October 16, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29124456/serial-immunological-parameters-in-a-phase-ii-trial-of-exemestane-and-low-dose-oral-cyclophosphamide-in-advanced-hormone-receptor-positive-breast-cancer
#20
Maryann Kwa, Xiaochun Li, Yelena Novik, Ruth Oratz, Komal Jhaveri, Jennifer Wu, Ping Gu, Marleen Meyers, Franco Muggia, James Speyer, Alyssa Iwano, Maryam Bonakdar, Lina Kozhaya, Ece Tavukcuoglu, Bahar Budan, Roy Raad, Judith D Goldberg, Derya Unutmaz, Sylvia Adams
BACKGROUND AND PURPOSE: Resistance to endocrine therapies in hormone receptor (HR)-positive breast cancer is a significant challenge. Prior studies have shown that low-dose oral cyclophosphamide can transiently deplete regulatory T cells (Tregs) and improve anti-tumor immunity. We investigated the combination of exemestane with cyclophosphamide in patients with advanced HR-positive breast cancer and assessed changes in circulating immune cell subsets. METHODS: This was a single-arm phase II trial of exemestane with cyclophosphamide in patients with metastatic HR-positive/HER2-negative breast cancer who had progressed on prior endocrine therapy (ClinicalTrials...
November 9, 2017: Breast Cancer Research and Treatment
keyword
keyword
11985
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"